TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32441833
Drug: L-arginine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (5 g)
Study: 32441833
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg)
Study: 32441833
Drug: Combined L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined L-arginine (5 g) with tadalafil (5 mg)
Study: 32346743
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy with motor imagery (MI) principles
Study: 34564686
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone 2mg/5ml
Study: 34564686
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 100mg/ml
Study: 32353115
Drug: Cosyntropin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosyntropin (70 μg/hour for 2.5 hours)
Study: 35943903
Drug: Online peer
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online peer support intervention based on acceptance and commitment therapy
Study: 34481070
Drug: Computer-generated smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated smoking cessation pharmacotherapy recommendation algorithm integrated into HIV primary care
Study: 36332361
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) with paracetamol
Study: 35527651
Drug: Stimunex® gocce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimunex® gocce (food supplement) given daily for 4 months
Study: 35527651
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for respiratory infections (Control group)
Study: 35527651
Drug: Stimunex® gocce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimunex® gocce (food supplement)
Study: 35410930
Drug: Reusable catheters
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reusable catheters replaced every 2 weeks and cleaning solution replaced every 24 hours
Study: 34226231
Drug: Daily patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily patient contact
Study: 32856272
Drug: Single RAS
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single RAS blocker therapy
Study: 32856272
Drug: Dual RAS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual RAS blocker therapy
Study: 32856272
Drug: Both single
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both single and dual RAS blocker therapy
Study: 32118792
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (t=0) - teeth extracted without orthodontic treatment
Study: 33914319
Drug: TachoSil (collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil (collagen patches coated with human coagulation factors)
Study: 33970657
Drug: Dynamic therapy
Normalized name: AVOBENZONE 3 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL / OXYBENZONE 6 g in 100 mL TOPICAL LOTION [PHOTO DYNAMIC THERAPY SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic therapy
Study: 35337389
Drug: Lifestyle advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle advice with or without metformin
Study: 33789580
Drug: Quetiapine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 12.5 mg once daily at bedtime for a maximum of 7 days
Study: 33789580
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily at bedtime for a maximum of 7 days
Study: 36133576
Drug: Task-based LSVT-BIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-based LSVT-BIG intervention (30 minutes of conventional occupational therapy and 40 minutes of task-based LSVT-BIG program, once a day, 5 times a week for 4 weeks)
Study: 36133576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 minutes of conventional occupational therapy and 40 minutes of relaxation and stretching, once a day, 5 times a week for 4 weeks)
Study: 35198517
Drug: IBA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBA plus speech therapy
Study: 35198517
Drug: IBA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBA plus inspiratory muscle training and speech therapy
Study: 35198517
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (surgical)
Study: 36280988
Drug: Manual lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual lumbar decompression, lumbar mobilisation, hot packs, TENS, and exercise therapy (Group A - acute)
Study: 36280988
Drug: Lumbar mobilisation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar mobilisation, hot packs, and exercise therapy (Group C - control)
Study: 36280988
Drug: Lumbar mobilisation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar mobilisation, hot packs, and exercise therapy (Group B - chronic)
Study: 34677151
Drug: Zufa syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zufa syrup (7.5 mL every 4 hours for 10 days)
Study: 34677151
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (identical-looking, 7.5 mL every 4 hours for 10 days)
Study: 34677151
Drug: Zufa syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zufa syrup
Study: 37304656
Drug: Movement meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement meditation (all doses)
Study: 37304656
Drug: Sitting meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting meditation (all doses)
Study: 33103229
Drug: ACTH therapy
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH therapy
Study: 35334969
Drug: Curcumin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1000 mg) with ONS
Study: 34932018
Drug: Scoring model
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring model based on risk factors (CgA, creatinine, previous chemotherapy)
Study: 33001236
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg levosimendan
Study: 35041042
Drug: Dexamethasone (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.30 mg per kg/day, intravenous, twice daily for 3 days)
Study: 34757600
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 5.6 mmol/L
Study: 34757600
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 6.1 mmol/L
Study: 34757600
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 7.0 mmol/L
Study: 35485815
Drug: Oxidised dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidised dextran (ANDROEXPERT SV1) suppositories, rectally once per day for 10 days, then every other day for 20 days.
Study: 35485815
Drug: Placebo (cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cocoa butter) suppositories, rectally in a similar regimen.
Study: 36123964
Drug: Codeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (60 mg/day for 2 weeks)
Study: 36123964
Drug: Levodropropizine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine (180 mg/day for 2 weeks)
Study: 35286750
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C-G, 22 patients)
Study: 36189778
Drug: Behavioral strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral strategies (e.g., prompting and rewards)
Study: 33485454
Drug: BPD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPD and RYGB (compared to medical therapy)
Study: 32195954
Drug: Paraffin therapy
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin therapy (20 minutes)
Study: 32195954
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no paraffin therapy)
Study: 35147680
Drug: AmBisome monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome monotherapy (40mg/kg intravenous liposomal amphotericin B administered in 8 equal doses over 24 days)
Study: 35147680
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (30mg/kg intravenous liposomal amphotericin B administered in 6 equal doses over 24 days + 1.4g oral miltefosine administered in two daily doses of 50mg over 14 days)
Study: 35147680
Drug: AmBisome monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome monotherapy (excluding those with concurrent tuberculosis)
Study: 35147680
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (excluding those with concurrent tuberculosis)
Study: 33382101
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) as an adjunct to scaling and root planing (ScRp)
Study: 34993386
Drug: Aspirin-sensitive patients
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-sensitive patients
Study: 34993386
Drug: Aspirin-resistant patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-resistant patients
Study: 33119948
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g day‐1 RS‐enriched potatoes (approximately two potatoes; 18 g RS)
Study: 33026166
Drug: BACPPI (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACPPI (20 mg of rabeprazole, 1000 mg of amoxicillin, 500 mg of clarithromycin, and 220 mg of bismuth potassium citrate) for 10 days
Study: 33026166
Drug: BACPPI (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACPPI (20 mg of rabeprazole, 1000 mg of amoxicillin, 500 mg of clarithromycin, and 220 mg of bismuth potassium citrate) for 14 days
Study: 32639057
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly 100 mg kg‐1 BW‐1 (RJ100)
Study: 32639057
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly 200 mg kg‐1 BW‐1 (RJ200)
Study: 32129161
Drug: Darunavir-ritonavir (DRV/r)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir-ritonavir (DRV/r) plus rilpivirine (RPV) once daily (QD)
Study: 34907523
Drug: Ultrasound-guided multiple-injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided multiple-injection costotransverse block (MICB) with three injections of 10 ml of ropivacaine (5 mg/ml)
Study: 34907523
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with three injections of 10 ml of saline (0.9%)
Study: 34907523
Drug: Ultrasound-guided multiple-injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided multiple-injection costotransverse block (MICB)
Study: 32957332
Drug: Shexiang Tongxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Tongxin dropping pill (STDP)
Study: 33393630
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fish oil/day (1.1 g eicosapentaenoic acid (EPA) + 0.8 g DHA)
Study: 33393630
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g corn oil/day (placebo)
Study: 32850414
Drug: IMRT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT combined with concurrent cisplatin (CCRT group)
Study: 32652092
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 0.9%) spray
Study: 34826225
Drug: Ritlecitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (oral JAK3-selective inhibitor)
Study: 37203336
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance
Study: 32721994
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postprandial levels of insulin, leptin, glucose, and ghrelin
Study: 33404656
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 mg/day)
Study: 34213870
Drug: Ozone/oxygen injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone/oxygen injection (25 mu-g/mL in 20 mL)
Study: 34213870
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (40mg) and lidocaine (40mg in 20 mL)
Study: 32109160
Drug: High-dose SVF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SVF
Study: 32109160
Drug: Low-dose SVF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SVF
Study: 34845913
Drug: Single-species mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-species mite allergen immunotherapy
Study: 34845913
Drug: Double-species mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-species mite allergen immunotherapy
Study: 34480096
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (anthracycline or taxane)
Study: 32270631
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) combined with conventional western medicine
Study: 33754604
Drug: Intracorporeal injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal injection (ICI)
Study: 33754604
Drug: Intracorporeal injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal injection (ICI) + phosphodiesterase inhibitor (PDE5i)
Study: 33754604
Drug: Phosphodiesterase inhibitor
Normalized name: Phosphodiesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase inhibitor (PDE5i)
Study: 35220651
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MELD and CYFRA21‐1
Study: 32243651
Drug: 5 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng/mL recombinant basic fibroblast growth factor (bFGF) and 25 mg/500 mL 3′5′ cyclic adenosine monophosphate (cAMP) (Group B)
Study: 32621663
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide 0.1% ointment twice daily for 2 weeks
Study: 32621663
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.03% ointment twice daily for 2 weeks
Study: 32574517
Drug: Antifibrotic drugs
Normalized name: Antihidrotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic drugs
Study: 36184966
Drug: Park prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Park prescription (Park Rx) during routine clinical visits
Study: 34922649
Drug: Namilumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab (150 mg, single intravenous dose)
Study: 34922649
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg, single intravenous dose)
Study: 32558214
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (HoT) after 4–8 weeks of inpatient treatment, with visits by a multi-professional team 3-4 times per week for the first two months and 1-2 times per week for the third and fourth months.
Study: 34052365
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen
Study: 34664829
Drug: CT nano-contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT nano-contrast agent
Study: 34664829
Drug: Traditional iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional iohexol contrast agent
Study: 34936270
Drug: Oral sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sertraline hydrochloride dispersible tablets, 50 mg once a day
Study: 35943472
Drug: Stenting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting plus medical therapy (n=176)
Study: 35943472
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (n=182)
Study: 35943472
Drug: Stenting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting plus medical therapy (n=171)
Study: 35943472
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (n=178)
Study: 35943472
Drug: Stenting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting plus medical therapy (n=168)
Study: 35943472
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (n=170)
Study: 35943472
Drug: Stenting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting plus medical therapy (n=160)
Study: 35943472
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (n=159)
Study: 35434041
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum Lp3a; 2×1.0×10^10 CFU for 7 days
Study: 35198149
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D daily
Study: 33901574
Drug: Pharmacogenetic optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic optimization arm (varenicline for fast metabolizers, nicotine patch for slow metabolizers)
Study: 34296374
Drug: Pivotal response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal response treatment (PRT), conducted three times a week for 2 months, totaling 24 one-hour sessions
Study: 35500453
Drug: 3-day high-fat
Normalized name: olive oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day high-fat diet (500 mL of cream, 1700 kcal)
Study: 34666728
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg every night at bedtime
Study: 34666728
Drug: Pumpkin seed
Normalized name: PUMPKIN SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpkin seed oil 360 mg twice a day
Study: 32763240
Drug: SER-287 after
Normalized name: SER-287
DrugBank: SER-287 (DB18204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-287 after vancomycin preconditioning (daily dosing)
Study: 32763240
Drug: SER-287 (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-287 (weekly dosing)
Study: 32763240
Drug: SER-287 (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-287 (weekly dosing after vancomycin)
Study: 32873473
Drug: Fluoroquinolone (usually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone (usually levofloxacin) monotherapy, 54% of treatments in both settings
Study: 34850428
Drug: 0.1% pH‐balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% pH‐balanced chlorine dioxide spray
Study: 34850428
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water spray (placebo control)
Study: 34547400
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of lipopolysaccharide (LPS) at a dose of 0.6 ng/kg body weight
Study: 33370165
Drug: Salacia chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia chinensis extract (150, 300, or 600 mg)
Study: 33370165
Drug: Salacia chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia chinensis extract (600 mg/day)
Study: 36484021
Drug: Loxoprofen Sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen Sodium Cataplasm combined with extracorporeal shock wave therapy (ESWT) and transcutaneous electrical nerve stimulation (TENS)
Study: 35215461
Drug: Nutrition and
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition and exercise intervention (bi‐weekly counselling for individualized energy and high dairy protein diet; walking goal of 10,000 steps/day)
Study: 32758298
Drug: Intravenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous melatonin (IVM) 5 mg/kg/day for 7 days
Study: 32758298
Drug: Placebo 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg/kg/day for 7 days
Study: 34554015
Drug: Optimal allocation
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal allocation to treatments in a sequential multiple assignment randomized trial
Study: 34091468
Drug: Steroid Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid Injection
Study: 34940059
Drug: TSH concentration
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH concentration <0.1 µU/mL
Study: 34940059
Drug: TSH concentration
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH concentration 0.4‐4.0 µU/mL
Study: 34940059
Drug: TSH concentration
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH concentration 0.1‐0.39 µU/mL
Study: 32728920
Drug: NAMI Provider
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAMI Provider Education Program - a 15-h contact-based adjunctive curriculum
Study: 34036235
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (Bev plus CTx)